SCHEMBL23533899

SCHEMBL23533899

O=C(Nc1ccncc1)c1n[nH]c2ccc(-c3cc4ccccc4s3)cc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 1/20 0.56
DYRK1A Q13627 14/20 0.52
CLK2 P49760 3/20 0.52
CLK3 P49761 2/20 0.52
WNT1 P04628 9/20 0.49
CDK2 P24941 2/20 0.49
DYRK3 O43781 1/20 0.49
MAP4K4 O95819 1/20 0.49
CDK1 P06493 1/20 0.49
MARK3 P27448 1/20 0.49
GSK3B P49841 1/20 0.49
CSNK2A1 P68400 1/20 0.49
CSNK1G2 P78368 1/20 0.49
CDK5 Q00535 1/20 0.49
MAP4K2 Q12851 1/20 0.49
PRKAA1 Q13131 1/20 0.49
CAMK2B Q13554 1/20 0.49
CAMK2G Q13555 1/20 0.49
CAMK2D Q13557 1/20 0.49
NTRK3 Q16288 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL81513 0.80 DYRK1A (0.56) DYRK1ACLK2CLK3WNT1CDK2
SCHEMBL82655 0.79 DYRK1A (0.70) DYRK1ACLK2CLK3WNT1CDK2
SCHEMBL5716427 0.77 DYRK1A (0.82) DYRK1ACLK2CLK3WNT1
Hydrochloric Acid SCHEMBL952393 0.76 DYRK1A (0.80) DYRK1ACLK2CLK3WNT1
SCHEMBL23533919 0.76 DYRK1A (0.63) DYRK1ACLK2CLK3WNT1CDK2
SCHEMBL30026349 0.75 FLT3 (0.81) CDK2CSNK2A1CCNA2FLT3CCNA1
SCHEMBL952896 0.75 DYRK1A (0.62) TBK1DYRK1ACLK2CLK3WNT1
SCHEMBL4531693 0.74 FLT3 (0.55) DYRK1ACLK2CLK3WNT1CDK2
SCHEMBL4520668 0.74 FLT3 (0.55) DYRK1ACLK2CLK3WNT1CDK2
SCHEMBL17108749 0.74 DYRK1A (0.80) DYRK1AWNT1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243181-A2 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-07-31 US claimed
CN-114867718-B Indazole derivatives and use thereof 韩国化学研究院 2024-10-01 CN claimed
US-20230116733-A1 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OFCHEMICAL TECHNOLOGY (KR) 2023-04-13 US claimed
EP-4079732-A1 NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2022-10-26 EP claimed
CN-114867718-A Novel indazole derivative and use thereof 韩国化学研究院 2022-08-05 CN claimed
WO-2021125802-A1 NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF 한국화학연구원 2021-06-24 WO claimed
US-20250243181-A2 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-07-31 US disclosed
CN-114867718-B Indazole derivatives and use thereof 韩国化学研究院 2024-10-01 CN disclosed
US-20230116733-A1 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OFCHEMICAL TECHNOLOGY (KR) 2023-04-13 US disclosed
EP-4079732-A1 NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2022-10-26 EP disclosed
CN-114867718-A Novel indazole derivative and use thereof 韩国化学研究院 2022-08-05 CN disclosed
WO-2021125802-A1 NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF 한국화학연구원 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243181-A2 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF TRIB2, YAP1, IDO2 TBK1 68/4885DYRK1A 573/4885CLK2 342/4885
US-20230116733-A1 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF TRIB2, YAP1, IDO2 TBK1 68/4885DYRK1A 573/4885CLK2 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.